
MDB Capital (NASDAQ:MDBH) plans to cut expenses and seek separate financing or partners for two of its businesses as it focuses on bringing four key assets closer to commercialization, CEO and Co-Founder Chris Marlett said during an update for the quarter ended September 30, 2026.
Marlett said the company expects to distribute assets to shareholders in 2027, with the board reviewing the timing and structure. He cautioned that financing needs and a difficult market for small companies remain risks to that plan.
“Our goal is to deliver as much out to the shareholders in 2027 as possible,” Marlett said. He added that MDB is focused on helping its four principal assets—Public Ventures, PatentVest, eXoZymes and Paulex Bio—reach value inflection points before distributions.
Financing and expense plans
MDB recorded approximately $4.2 million in fee income for the first nine months of 2026, up from the prior-year period, Marlett said. He said costs remained relatively steady and that the company had about $8.3 million in operating cash.
MDB is working on financings and partnerships for Public Ventures and PatentVest that Marlett said could reduce the parent company’s cash spending and extend its runway. The goal, he said, is to avoid raising additional capital at MDB while its assets advance.
Marlett said MDB has not launched as many new companies as it had hoped because of constrained access to capital and depressed valuations. He also noted that financing transactions for eXoZymes and Paulex are subject to market conditions.
Public Ventures and PatentVest seek scale
Public Ventures, MDB’s self-clearing broker-dealer platform, is in discussions with several potential partners that understand how to scale clearing operations, Marlett said. He said a transaction could help the platform expand beyond its current business and realize value.
For PatentVest, an intellectual property law firm, Marlett said MDB plans to complete a financing to support marketing and sales. He said the firm has built an AI-assisted platform that combines business and IP strategy with patent work.
Marlett said PatentVest has demonstrated that it can take an invention through preparation and filing of a patent application in one day, a process he said previously took months. He also said the platform has the capacity to process 1,000 patent applications a year. PatentVest still needs to expand its client base, and Marlett said the company believes it can become profitable relatively quickly with limited additional capital.
eXoZymes pursues partners
At eXoZymes, which uses enzymes in a cell-free synthetic biology process, Marlett said the company has demonstrated that its manufacturing process can scale and has developed a pipeline beyond its initial product, NCT. He said the company has reduced the anticipated manufacturing cost of a compound from an initial estimate of $3,500 per kilogram to under $1,000 per kilogram.
Marlett said eXoZymes is seeking marketing and pharmaceutical partners to bring compounds to market, while focusing itself on discovery and manufacturing. He also said MDB hopes a new company focused on cannabinoids could eventually be spun out of eXoZymes, though he did not provide a timetable.
MDB President and Head of Community Development George Brandon said eXoZymes was in the middle of a financing under a filed S-1 registration statement, limiting what the executives could discuss beyond the filing.
Paulex trial and distribution outlook
Paulex Bio is developing a small-molecule drug licensed from Mount Sinai that aims to enable the regrowth of insulin-producing beta cells. Marlett said the company raised a $19 million seed round and now expects to begin dosing the first clinical-trial participants in December, roughly two months later than previously anticipated.
The initial milestone will be establishing safety, he said, with efficacy also a critical question. Marlett cited preclinical research involving human cells in animals as a reason for confidence, while emphasizing the importance of the upcoming clinical milestones.
Paulex has confidentially filed a registration statement and would like to go public in the first half of 2027, according to Marlett. He also said MDB is exploring ways to take Public Ventures and potentially PatentVest public, which could make distributing those assets easier.
eXoZymes is already public, but Marlett said he would prefer to see it reach an inflection point and complete financing before distributing its shares. He noted that its trading volume is currently low.
About MDB Capital (NASDAQ:MDBH)
MDB Capital (NASDAQ: MDBH) is a financial services firm specializing in investment banking and capital markets services for innovative and emerging-growth companies. It advises businesses on financing and strategic transactions and supports capital raising through public and private offerings. The company also provides intellectual-property advisory services, including analysis and strategy to help businesses develop and commercialize their patent portfolios. Its services combine corporate finance expertise with support for technology-driven companies.
